Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer

Home > Science Hub > Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer
Back to the list

April 12, 2022

Dirix L et al. Breast Cancer Research and Treatments, 2022

Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer

Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer

Download Publication

You might also be interested by

Web News

The CellCarta–Leica Biosystems Partnership: A Coordinated Approach to CDx Development in China

May 8, 2026

More info

Posters

High quality whole transcriptome RNA-sequencing from challenging clinical samples

April 21, 2026

More info

Posters

Scaling Liquid Biopsy Biomarker Discovery: multi-center, Analytical Validation of high resolution ctDNA Profiling Using TSO500 ctDNA v2.0 on NovaSeq X Plus

April 20, 2026

More info

Brochures & Infographics

Genomic Assay List

April 15, 2026

More info